Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (15022)	2/13/1998 7:28:00 PM
From: Henry Niman	Respond to of 32384

David, It is true that a Phase I trial in one group may not be an appropriate Phase I trial in another, but the distinction was made between advanced cancer patients where it's hard to do harm (most will not respond to approved therapies) and another group that may have an early form of a non-fatal disease that can be managed by approved drugs. Thus the Phase I trials for one form of advanced cancer will be appropriate for another advanced cancer, but not a chronic disease like type II diabetes. LGND's breast cancer trials will start with patients who have advanced breast cancer, and the Phase I trials on other patients with other advanced malignancies will allow LGND to begin breast cancer trials at the Phase II level. After reading the breast cancer paper in Cancer Research, it seems that they have many promising options, and I think that they are trying to figure out just how many trials they want to run, not whether they should do a Phase I or II trial (although combination trials could be delayed if the have to start at Phase I - maybe they will let LLY blaze some trails for the combination trials)